POXEL S.A. (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today its results for the first half of 2018 ended June 30, 2018, and provided a corporate update.
September 19, 2018
· 13 min read